Targeting intracellular cholesterol imbalance rescues sarcomere–ER contact site signaling and ER remodeling in dilated cardiomyopathy

Autor/innen

  • Nadezda Ignatyeva
  • Cleophas Cheruiyot
  • Hafiza Nosheen Saleem
  • Ruheen Wali
  • Daria Plota
  • Wenjing Zhang
  • Sophie Schön
  • Soeren Brandenburg
  • Zhengyi Yang
  • Anna Steyer
  • Henning Urlaub
  • Torsten Rasmussen
  • Jens Mogensen
  • Julius Ryan D. Pronto
  • Yannic Döring
  • Michael H. Radke
  • Halyna Shcherbata
  • Stephan E. Lehnart
  • Andreas Janshoff
  • Samuel Sossalla
  • Torben Ruhwedel
  • Wiebke Moebius
  • Karl Toischer
  • Britta Brügger
  • Volver Haucke
  • Michael Gotthardt
  • Niels Voigt
  • Antje Ebert

Journal

  • Signal Transduction and Targeted Therapy

Quellenangabe

  • Signal Transduct Target Ther 11 (1): 237

Zusammenfassung

  • Dysregulated intracellular lipid metabolism emerged as a driver of heart failure (HF), a leading cause of death worldwide that is frequently caused by dilated cardiomyopathy (DCM). Yet, how defective lipid signaling destabilizes failing cardiomyocytes (CMs) at the molecular level remains elusive. We utilized induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs), patient-derived heart tissue, and living adult CMs to elucidate lipid-dependent endoplasmic reticulum (ER) dysregulation in DCM and HF and identify new therapeutic targets. Lipidomics revealed abnormal intracellular cholesterol in iPSC-CMs carrying DCM-causing mutations in sarcomere proteins (tropomyosin; troponin T). Elevated cholesterol in CMs was found linked to abnormal ER architecture and dysfunction. STED microscopy, electron tomography, and biochemical analyses demonstrated that pathological ER remodeling and abnormal curvature are triggered by loss of ER-sarcomere/cytoskeleton contacts due to sarcomere misalignment in DCM CMs. Mechanistically, this signaling axis levers ER membrane dysfunctions and abnormal cholesterol levels via ER-sarcomere contact sites and operates in a bidirectional manner. Restoring intracellular cholesterol balance rescued ER membrane remodeling, sarcomere-ER contact site signaling, and sarcomere disarray in DCM iPSC-CMs. This ultimately improved the defective contractility of DCM iPSC-CMs, a key feature of failing CMs that contain a misaligned, dysfunctional sarcomere cytoskeleton. We validated this pathomechanism in end-stage DCM hearts and living atrial cardiomyocytes. Our findings suggest that intracellular cholesterol functions as a conserved ER membrane modulator and structural determinant across human CMs. Taken together, we present the lipidomic landscape of DCM and identify defective ER/cholesterol signaling as a disease driver whose therapeutic targeting rescues key functions in failing CMs.


DOI

doi:10.1038/s41392-026-02731-3